On November 18, Recursion Pharmaceuticals, Inc. fell 5.33% in Regular Trading, trading at $2.7501 per share, with turnover of $21.9626 million.
The clearest catalyst in recent market updates is that enthusiasm following the company’s REC-4881 Phase 2 data update has continued to fade, with investors refocusing on the timing and prospects of a registrational trial and the scope for valuation recovery.
Recent disclosures said updated TUPELO Phase 1b/2 data showed REC-4881 delivered deep and durable reductions in polyp burden in familial adenomatous polyposis, with a relatively clean safety profile that supports advancing toward a registrational study. Separately, third-quarter revenue was $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, in line with expectations. The company also previously raised about $200 million through a stock offering and disclosed a $10 million milestone tied to Sanofi’s optioning of a collaboration candidate, providing additional business context but not altering the market’s current focus on REC-4881 execution.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments